Determinants of high on-treatment platelet reactivity and agreement between VerifyNow and Multiplate assays

References

• Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Ganiats TG, Holmes DR, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJ. American College of Cardiology, American Heart Association Task Force on Practice Guidelines, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Clinical Chemistry. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;64:e139–228.
   PubMed Web of Science ®Google Scholar
• Windecker S, Kolh P, Alfonso F, Collet J-P, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann F-J, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS guidelines on myocardial revascularization. EuroIntervention J Eur Collab Work Group Interv Cardiol Eur Soc Cardiol 2015;10:1024–94.
   Google Scholar
• Montalescot G, Sabatine MS. Oral dual antiplatelet therapy: what have we learnt from recent trials? Eur Heart J 2016;37:344–52.
   PubMed Web of Science ®Google Scholar
• Snoep JD, Hovens MMC, Eikenboom JCJ, van der Bom JG, Jukema JW, Huisman MV. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 2007;154:221–31.
   PubMed Web of Science ®Google Scholar
• Sofi F, Marcucci R, Gori AM, Giusti B, Abbate R, Gensini GF. Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. Thromb Haemost 2010;103:841–8.
   PubMed Web of Science ®Google Scholar
• Niu X, Mao L, Huang Y, Baral S, Li J, Gao Y, Xia Y, He Q, Wang M, Li M, Zou L, Miao X, Hu B. CYP2C19 polymorphism and clinical outcomes among patients of different races treated with clopidogrel: a systematic review and meta-analysis. J Huazhong Univ Sci Technolog Med Sci 2015;35:147–56.
   PubMed Web of Science ®Google Scholar
• Liu R, Zhou Z-Y, Chen Y-B, Li J-L, Yu W-B, Chen X-M, Zhao M, Zhao Y-Q, Cai Y-F, Jin J, Huang M. Associations of CYP3A4, NR1I2, CYP2C19 and P2RY12 polymorphisms with clopidogrel resistance in Chinese patients with ischemic stroke. Acta Pharmacol Sin 2016;37:882–8.
   PubMed Web of Science ®Google Scholar
• Luo M, Li J, Xu X, Sun X, Sheng W. ABCB1 C3435T polymorphism and risk of adverse clinical events in clopidogrel treated patients: a meta-analysis. Thromb Res 2012;129:754–9.
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM, Jilma B, Schrör K, Christ G, Huber K. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. J Thromb Haemost 2010;8:2624–41.
   PubMed Web of Science ®Google Scholar
• Pelliccia F, Rosano G, Marazzi G, Vitale C, Spoletini I, Franzoni F, Speziale G, Polacco M, Greco C, Gaudio C. Pharmacodynamic comparison of pitavastatin versus atorvastatin on platelet reactivity in patients with coronary artery disease treated with dual antiplatelet therapy. Circ J 2014;78:679–84.
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Loomba RS, Arora RR. Effects of concurrent calcium channel blocker on antiplatelet efficacy of clopidogrel therapy: a systematic review. Am J Ther 2016;23:e29–36.
   PubMed Web of Science ®Google Scholar
• Reny J-L, Fontana P, Hochholzer W, Neumann FJ, Ten Berg J, Janssen PW, Geisler T, Gawaz M, Marcucci R, Gori A-M, Cuisset T, Alessi M-C, Berdagué P, Gurbel PA, Yong G, Angiolillo DJ, Aradi D, Beigel R, Campo G, Combescure C. Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel. Systematic review and meta-analysis of individual patient data. Thromb Haemost 2016;115:844–55.
   PubMed Web of Science ®Google Scholar
• Aradi D, Storey RF, Komócsi A, Trenk D, Gulba D, Kiss RG, Husted S, Bonello L, Sibbing D, Collet J-P, Huber K. Working Group on Thrombosis of the European Society of Cardiology. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J 2014;35:209–15.
   PubMed Web of Science ®Google Scholar
• Woo K-S, Kim B-R, Kim J-E, Goh R-Y, Yu L-H, Kim M-H, Han J-Y. Determination of the prevalence of aspirin and clopidogrel resistances in patients with coronary artery disease by using various platelet-function tests. Korean J Lab Med 2010;30:460–8.
   PubMedGoogle Scholar
• Consuegra-Sánchez L, López-Palop R, Cano P, Carrillo P, Picó F, Villegas M, Sanchis J, Kaski JC. Assessment of high on-treatment platelet reactivity in patients with ischemic heart disease: concordance between the Multiplate and VerifyNow assays. J Thromb Haemost 2013;11:379–81.
   PubMed Web of Science ®Google Scholar
• Cattaneo M. High on-treatment platelet reactivity-definition and measurement. Thromb Haemost 2013;109:792–8.
   PubMed Web of Science ®Google Scholar
• Tantry US, Bonello L, Aradi D, Price MJ, Jeong Y-H, Angiolillo DJ, Stone GW, Curzen N, Geisler T, Ten Berg J, Kirtane A, Siller-Matula J, Mahla E, Becker RC, Bhatt DL, Waksman R, Rao SV, Alexopoulos D, Marcucci R, Reny J-L, Trenk D, Sibbing D, Gurbel PA. Working Group on On-Treatment Platelet Reactivity. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013;62:2261–73.
   PubMed Web of Science ®Google Scholar
• Price MJ, Angiolillo DJ, Teirstein PS, Lillie E, Manoukian SV, Berger PB, Tanguay J-F, Cannon CP, Topol EJ. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation 2011;124:1132–7.
   PubMed Web of Science ®Google Scholar
• Brar SS, ten Berg J, Marcucci R, Price MJ, Valgimigli M, Kim H-S, Patti G, Breet NJ, DiSciascio G, Cuisset T, Dangas G. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol 2011;58:1945–54.
   PubMed Web of Science ®Google Scholar
• Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, Buonamici P, Antoniucci D, Abbate R, Gensini GF. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009;119:237–42.
   PubMed Web of Science ®Google Scholar
• Giusti B, Gori AM, Marcucci R, Saracini C, Sestini I, Paniccia R, Valente S, Antoniucci D, Abbate R, Gensini GF. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics 2007;17:1057–64.
   PubMed Web of Science ®Google Scholar
• Droździk M, Myśliwiec K, Lewińska-Chelstowska M, Banach J, Droździk A, Grabarek J. P-glycoprotein drug transporter MDR1 gene polymorphism in renal transplant patients with and without gingival overgrowth. J Clin Periodontol 2004;31:758–63.
   PubMed Web of Science ®Google Scholar
• Danielak D, Karaźniewicz-Łada M, Wiśniewska K, Bergus P, Burchardt P, Komosa A, Główka F. Impact of CYP3A4*1G allele on clinical pharmacokinetics and pharmacodynamics of clopidogrel. Eur J Drug Metab Pharmacokinet 2017;42:99–107.
   PubMed Web of Science ®Google Scholar
• Sim SC, Risinger C, Dahl M-L, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin. Pharmacol Ther 2006;79:103–13.
   PubMed Web of Science ®Google Scholar
• Tantry US, Bliden KP, Wei C, Storey RF, Armstrong M, Butler K, Gurbel PA. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. Circ Cardiovasc Genet 2010;3:556–66.
   PubMed Web of Science ®Google Scholar
• Kim YG, Suh J-W, Park JJ, Oh I-Y, Yoon C-H, Cho Y-S, Youn T-J, Chae I-H, Choi D-J. Different influences of hematocrit on the results of two Point-Of-Care platelet function tests, the VerifyNow assay and multiple electrode platelet aggregometry. PLoS One 2014;9:e114053.
   PubMed Web of Science ®Google Scholar
• Kakouros N, Kickler TS, Laws KM, Rade JJ. Hematocrit alters VerifyNow P2Y12 assay results independently of intrinsic platelet reactivity and clopidogrel responsiveness. J Thromb Haemost 2013;11:1814–22.
   PubMed Web of Science ®Google Scholar
• Pendyala LK, Loh JP, Lhermusier T, Minha S’, Magalhaes MA, Torguson R, Chen F, Satler LF, Pichard AD, Waksman R. Does baseline hematocrit influence the assays of on-treatment platelet reactivity to clopidogrel? Am Heart J 2014;168:545–51.
   PubMed Web of Science ®Google Scholar
• Bell DN, Spain S, Goldsmith HL. Extracellular-free Ca++ accounts for the sex difference in the aggregation of human platelets in citrated platelet-rich plasma. Thromb Res 1990;58:47–60.
   PubMed Web of Science ®Google Scholar
• Tsujita K, Nikolsky E, Lansky AJ, Dangas G, Fahy M, Brodie BR, Dudek D, Möckel M, Ochala A, Mehran R, Stone GW. Impact of anemia on clinical outcomes of patients with ST-segment elevation myocardial infarction in relation to gender and adjunctive antithrombotic therapy (from the HORIZONS-AMI Trial). Am J Cardiol 2010;105:1385–94.
   PubMed Web of Science ®Google Scholar
• Sattur S, Harjai KJ, Narula A, Devarakonda S, Orshaw P, Yaeger K. The influence of anemia after percutaneous coronary intervention on clinical outcomes. Clin Cardiol 2009;32:373–9.
   PubMed Web of Science ®Google Scholar
• Toma C, Zahr F, Moguilanski D, Grate S, Semaan RW, Lemieux N, Lee JS, Cortese-Hassett A, Mulukutla S, Rao SV, Marroquin OC. Impact of anemia on platelet response to clopidogrel in patients undergoing percutaneous coronary stenting. Am J Cardiol 2012;109:1148–53.
   PubMed Web of Science ®Google Scholar
• Jilma-Stohlawetz P, Ratzinger F, Schörgenhofer C, Jilma B, Quehenberger P. Effect of preanalytical time-delay on platelet function as measured by multiplate, PFA-100 and VerifyNow. Scand J Clin Lab Invest 2016;76:249–55.
   PubMed Web of Science ®Google Scholar
• Ahn SG, Lee S-H, Yoon J-H, Kim WT, Lee J-W, Youn Y-J, Ahn M-S, Kim J-Y, Yoo B-S, Yoon J, Choe K-H. Different prognostic significance of high on-treatment platelet reactivity as assessed by the VerifyNow P2Y12 assay after coronary stenting in patients with and without acute myocardial infarction. JACC Cardiovasc Interv 2012;5:259–67.
   PubMed Web of Science ®Google Scholar
• Gremmel T, Kopp CW, Eichelberger B, Koppensteiner R, Panzer S. Sex differences of leukocyte-platelet interactions and on-treatment platelet reactivity in patients with atherosclerosis. Atherosclerosis 2014;237:692–5.
   PubMed Web of Science ®Google Scholar
• Clareus A, Fredriksson I, Wallén H, Gordon M, Stark A, Sköldenberg O. Variability of platelet aggregation in patients with clopidogrel treatment and hip fracture: a retrospective case-control study on 112 patients. World J Orthop 2015;6:439–45.
   PubMedGoogle Scholar
• Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA 2011;306:2704–14.
   PubMed Web of Science ®Google Scholar
• Mao L, Jian C, Changzhi L, Dan H, Suihua H, Wenyi T, Wei W. Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects. Arch Cardiovasc Dis 2013;106:517–27.
   PubMed Web of Science ®Google Scholar
• Pettersen A-AR, Arnesen H, Opstad TB, Seljeflot I. The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel. Thromb J 2011;9:4.
   PubMedGoogle Scholar
• Karaźniewicz-Łada M, Danielak D, Rubiś B, Burchardt P, Oszkinis G, Główka F. The influence of genetic polymorphism of Cyp2c19 isoenzyme on the pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases. J Clin Pharmacol 2014;54:874–80.
   PubMed Web of Science ®Google Scholar
• Nakata T, Miyahara M, Nakatani K, Wada H, Tanigawa T, Komada F, Hoshino K, Aoki T, Nishimura Y, Tamaru S, Ito M, Nishikawa M. McLordd Group. Relationship between CYP2C19 loss-of-function polymorphism and platelet reactivities with clopidogrel treatment in Japanese patients undergoing coronary stent implantation. Circ J 2013;77:1436–44.
   PubMed Web of Science ®Google Scholar
• Yamaguchi Y, Abe T, Sato Y, Matsubara Y, Moriki T, Murata M. Effects of VerifyNow P2Y12 test and CYP2C19*2 testing on clinical outcomes of patients with cardiovascular disease: a systematic review and meta-analysis. Platelets 2013;24:352–61.
   PubMed Web of Science ®Google Scholar
• Osnabrugge RL, Head SJ, Zijlstra F, ten Berg JM, Hunink MG, Kappetein AP, Janssens ACJW. A systematic review and critical assessment of 11 discordant meta-analyses on reduced-function CYP2C19 genotype and risk of adverse clinical outcomes in clopidogrel users. Genet Med 2015;17:3–11.
   PubMed Web of Science ®Google Scholar
• Frelinger AL 3rd, Bhatt DL, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, Lampa M, Brooks JK, Barnard MR, Michelson AD. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol 2013;61:872–9.
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T, Antman EM, Braunwald E, Sabatine MS. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. The Lancet 2010;376:1312–19.
   PubMed Web of Science ®Google Scholar
• Karaźniewicz-Łada M, Danielak D, Rubiś B, Burchardt P, Komosa A, Lesiak M, Główka F. Impact of common ABCB1 polymorphism on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolites. J Clin Pharm Ther 2015;40:226–31.
   PubMed Web of Science ®Google Scholar
• Wang X-Q, Shen C-L, Wang B-N, Huang X-H, Hu Z, Li J. Genetic polymorphisms of CYP2C19 2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome. Gene 2015;558:200–7.
   PubMed Web of Science ®Google Scholar
• Correll M, Johnson CK, Ferrari G, Brizzio M, Mak AWC, Quackenbush J, Shaw RE, Zapolanski A, Grau JB. Mutational analysis clopidogrel resistance and platelet function in patients scheduled for coronary artery bypass grafting. Genomics 2013;101:313–17.
   PubMed Web of Science ®Google Scholar
• Jaitner J, Morath T, Byrne RA, Braun S, Gebhard D, Bernlochner I, Schulz S, Mehilli J, Schömig A, Koch W, Kastrati A, Sibbing D. No association of ABCB1 C3435T genotype with clopidogrel response or risk of stent thrombosis in patients undergoing coronary stenting. Circ Cardiovasc Interv 2012;5:82.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Cavallari U, Trabetti E, Sabate M, Hernandez R, Moreno R, Escaned J, Alfonso F, Banuelos C, Costa MA, Bass TA, Pignatti PF, Macaya C. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol 2006;26:1895–900.
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM, Lang I, Christ G, Jilma B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008;52:1557–63.
   PubMed Web of Science ®Google Scholar
• Seo K-D, Kim YD, Yoon Y-W, Kim J-Y, Lee K-Y. Antiplatelet effect of clopidogrel can be reduced by calcium-channel blockers. Yonsei Med J 2014;55:683–8.
   PubMed Web of Science ®Google Scholar
• Kirtane AJ, Parikh PB, Stuckey TD, Xu K, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann F-J, Metzger DC, Henry TD, Cox DA, Duffy PL, Brodie BR, Mazzaferri EL, Parvataneni R, Maehara A, Généreux P, Mehran R, Stone GW. Is there an ideal level of platelet P2Y12-receptor inhibition in patients undergoing percutaneous coronary intervention?: “Window” analysis from the ADAPT-DES study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents). JACC Cardiovasc Interv 2015;8:1978–87.
   PubMed Web of Science ®Google Scholar
• Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH. American College of Cardiology Foundation, American Heart Association Task Force on Practice Guidelines, Society for Cardiovascular Angiography and Interventions. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011;58:e44–122.
   PubMed Web of Science ®Google Scholar